molecules of the month


oral galectin-3 inhibitor

Ph. I/II candidate in cancer and liver diseases

LLE and PK opt. from a prev. clinical candidate

J. Med. Chem.

Galecto Biotech, Gothenburg, SE

GB1211 chemical structure oral galectin-3 inhibitor - Galecto Biotech, Gothenburg, SE
5 mins read

Context. GB1211 (Galecto Biotech) is an oral galectin-3 inhibitor under development for fibrotic disease. First described in 1971, galectin-3, a unique subtype of a 15-member family of carbohydrate-binding proteins, has been implicated in a host of different diseases, such as cancer, liver cirrhosis, and atherosclerosis. Incredibly, over 8000 papers featuring the protein have since been published. Despite the promise for drug discovery, key liabilities such as low affinity and/or limited bioavailability have precluded the clinical success of previously described galectin-3 inhibitors, challenges Galecto Biotech are hoping to overcome. GB1211, the flagship compound of a new class of α-d-monogalactopyranoside with nanomolar affinity and improved oral bioavailability, demonstrated promising preclinical efficacy and is currently in early clinical development for liver fibrosis and…

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: